U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C27H29NO3
Molecular Weight 415.5241
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ZAMIFENACIN

SMILES

C(CC1=CC=C2OCOC2=C1)N3CCC[C@H](C3)OC(C4=CC=CC=C4)C5=CC=CC=C5

InChI

InChIKey=BDNFQGRSKSQXRI-XMMPIXPASA-N
InChI=1S/C27H29NO3/c1-3-8-22(9-4-1)27(23-10-5-2-6-11-23)31-24-12-7-16-28(19-24)17-15-21-13-14-25-26(18-21)30-20-29-25/h1-6,8-11,13-14,18,24,27H,7,12,15-17,19-20H2/t24-/m1/s1

HIDE SMILES / InChI

Description

Zamifenacin, also known as UK-76654, a selective muscarinic M3 receptor antagonist, was studied in patients with irritable bowel syndrome (IBS). This drug participated in clinical trials for the IBS phase III in the USA and phase II in the UK, but these studies were discontinued.

Originator

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Muscarinic acetylcholine receptor M3
159
Target ID: P20309
Gene ID: 1131.0
Gene Symbol: CHRM3
Target Organism: Homo sapiens (Human)
Antagonist
2778
 8.52 null [pKi]
PubMed

PubMed

TitleDatePubMed
Characterization of the interaction of zamifenacin at muscarinic receptors in vitro.
1995 Oct 16
Zamifenacin (UK-76, 654) a potent gut M3 selective muscarinic antagonist, reduces colonic motor activity in patients with irritable bowel syndrome.
1997 Jun
In vitro toxicity of zamifenacin (UK-76,654) and metabolites in primary hepatocyte cultures.
1998 Sep
Patents

Patents

20050004155
2
JPH07157469A
2

Sample Use Guides

In Vivo Use Guide
single dose of zamifenacin 10 mg or 40 mg on both fasting (30 min) and fed (60 min)
Route of Administration: Oral
Name Type Language
ZAMIFENACIN
INN   MART.  
INN  
Official Name English
UK-76654-2 FREE BASE
Code English
zamifenacin [INN]
Common Name English
ZAMIFENACIN [MART.]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29704
Created by admin on Fri Dec 15 15:42:59 GMT 2023 , Edited by admin on Fri Dec 15 15:42:59 GMT 2023
Code System Code Type Description
ChEMBL
CHEMBL27507
Created by admin on Fri Dec 15 15:42:59 GMT 2023 , Edited by admin on Fri Dec 15 15:42:59 GMT 2023
PRIMARY
EVMPD
SUB00136MIG
Created by admin on Fri Dec 15 15:42:59 GMT 2023 , Edited by admin on Fri Dec 15 15:42:59 GMT 2023
PRIMARY
SMS_ID
100000079369
Created by admin on Fri Dec 15 15:42:59 GMT 2023 , Edited by admin on Fri Dec 15 15:42:59 GMT 2023
PRIMARY
EPA CompTox
DTXSID9047257
Created by admin on Fri Dec 15 15:42:59 GMT 2023 , Edited by admin on Fri Dec 15 15:42:59 GMT 2023
PRIMARY
NCI_THESAURUS
C66682
Created by admin on Fri Dec 15 15:42:59 GMT 2023 , Edited by admin on Fri Dec 15 15:42:59 GMT 2023
PRIMARY
FDA UNII
Y88Q418Y7M
Created by admin on Fri Dec 15 15:42:59 GMT 2023 , Edited by admin on Fri Dec 15 15:42:59 GMT 2023
PRIMARY
INN
6829
Created by admin on Fri Dec 15 15:42:59 GMT 2023 , Edited by admin on Fri Dec 15 15:42:59 GMT 2023
PRIMARY
PUBCHEM
3086618
Created by admin on Fri Dec 15 15:42:59 GMT 2023 , Edited by admin on Fri Dec 15 15:42:59 GMT 2023
PRIMARY
CAS
127308-82-1
Created by admin on Fri Dec 15 15:42:59 GMT 2023 , Edited by admin on Fri Dec 15 15:42:59 GMT 2023
PRIMARY
MESH
C097932
Created by admin on Fri Dec 15 15:42:59 GMT 2023 , Edited by admin on Fri Dec 15 15:42:59 GMT 2023
PRIMARY
ACTIVE MOIETY
Structure of ZAMIFENACIN
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966